Evaluate the Presence of Auto-Antibodies in Subjects with B- Thalassemia Major for Early Intervention to Decrease Morbidity and Mortality
Abstract
This study was performed of evaluate the presence of auto antibodies and hypercoagulability in subjects with β -thalassemia major. Subjects (60) with – β-thalassemia major were involved in the current work. History background, clinical tests and laboratory investigation including anti-cardiolipin antibodies anti-histone antibodies, ANA and anti-erythropoietin antibodies by ELISA, Ferritin by Cobas e411, protein S, protein C, and anti-thromobin III anti-bodies via ELISA. Findings of the study showed that there is elevated frequency of auto-antibodies in thalassemia major subjects, ANA was positive in 13.3% of cases, anti-histone antibodies was positive in 3.3% of cases, anti-cardiolipin antibodies in 15% and ant erythropoietin in 93.3% of cases. Protein C activity was deficient in 26.6% and protein S was deficient in deficient anti-thrombin III activity. Such abnormalities were not of significance associated to the HCV infection state or to the chelation type if subcutaneous or oral. Deficiency of protein C significantly existed in elder subjects.
References
Cappellini, M. D., Cohen, A., Eleftheriou, A., Piga, A., Porter, J., & Taher, A. (2008). Guidelines for the Clinical Management of Thalassaemia [Internet]. Nicosia (CY): Thalassaemia International Federation; 2008. Fe overload.[Google Scholar].
Sumera, A., Anuar, N. D., Radhakrishnan, A. K., Ibrahim, H., Rutt, N. H., Ismail, N. H., ... & Baba, A. A. (2020). A novel method to identify auto-antibodies against putative target proteins in serum from beta-thalassemia major: a pilot study. Biomedicines, 8(5), 97.
Taher, A. T., Otrock, Z. K., Uthman, I., & Cappellini, M. D. (2008). Thalassemia and hypercoagulability. Blood reviews, 22(5), 283-292.
Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet journal of rare diseases, 5(1), 1-15.
Chou, S. T., Liem, R. I., & Thompson, A. A. (2012). Challenges of alloimmunization in subjects with haemoglobinopathies. British journal of haematology, 159(4), 394-404.
El Kababi, S., Benajiba, M., El Khalfi, B., Hachim, J., & Soukri, A. (2019). Red blood cell alloimmunizations in beta-thalassemia subjects in Casablanca/Morocco: Prevalence and risk factors. Transfusion Clinique et Biologique, 26(4), 240-248.
Pavlovic, S., Ugrin, M., & Stojiljkovic, M. (2015). Novel Therapy Approaches in β-Thalassemia Syndromes–A Role of Genetic Modifiers. Inherited hemoglobin disorders. Rijeka: InTech, 137-160.
Sevim, E., Zisa, D., Andrade, D., Sciascia, S., Pengo, V., Tektonidou, M. G., ... & Barbhaiya, M. (2020). Characteristics of Antiphospholipid Antibody Positive Subjects in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Arthritis Care & Research.
Ghembaza, A., & Saadoun, D. Management of antiphospholipid syndrome. Biomedicines. 2020; 8 (11): 508.
Wang, D., Lv, W., Zhang, S., & Zhang, J. (2019). Advances in the research on anticardiolipin antibody. Journal of Immunology Research, 2019.
Chinsuwan, J., Klaihmon, P., Kadegasem, P., Chuansumrit, A., Soisamrong, A., Pattanapanyasat, K., ... & Sirachainan, N. (2020). High prevalence of antiphospholipid antibodies in children with non-transfusion dependent thalassemia and possible correlations with microparticles. Mediterranean Journal of Hematology and Infectious Diseases, 12(1).
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013). Non-transfusion-dependent thalassemias. haematologica, 98(6), 833.
Urbanus, R. T., Derksen, R. H., & de Groot, P. G. (2008). Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood reviews, 22(2), 93-105.
Siagris, D., Christofidou, M., Tsamandas, A., Lekkou, A., Thomopoulos, K., & Labropoulou-Karatza, C. (2004). Cryoglobulinemia and progression of fibrosis in chronic HCV infection: cause or effect?. Journal of Infection, 49(3), 236-241.
Giordano, P., Del Vecchio, G. C., Altomare, M., Coppola, B., Schettini, F., Lolascon, A., & De Mattia, D. (1998). Resistance to activated protein C in thalassaemic subjects: an underlying cause of thrombosis. European journal of haematology, 61(2), 123-127.
